About Us
The Innate Immune Regulation Research Unit was established in August 2022 and is based at Tsukuba Research Center in Japan. Our goal is to create highly effective drugs for intractable immune-related diseases such as chronic inflammatory disorders, allergy, organ fibrosis, and tissue degenerative diseases, focusing on innate immune regulation. Astellas has accumulated experience in the immunology area through research and development of multiple immunomodulatory drugs. As for the area of innate immunity, Astellas has targeted pattern recognition receptors and innate lymphoid cells and has achieved the discovery of several development candidates.
In the innate immune system, various cells including monocytes/macrophages, neutrophils, innate lymphoid cells, and natural killer cells interact with each other and are involved in the maintenance of homeostasis. The immune signaling network among these immune cells and surrounding tissue is considered to be disrupted and abnormal in a diseased state. We aim to develop truly valuable therapeutic agents through analysis of the immune microenvironment in diseases to find the molecular targets and pathways that play a central role in it.
Our Approach
We will identify causal drug targets through the analysis of genetic linkage for the disease and an understanding of the immune microenvironment. We will select an optimal modality from a variety of options, including small molecule compounds and modified antibodies, and promote a more efficient creation of drug candidates using AI and robotics.
Furthermore, we will increase the probability of success in clinical trials by actively promoting translational science research using clinical samples from the early stages of drug discovery.
Team
Unit Head
Takanori Koike, Ph.D.
Dr. Koike worked in drug discovery research as a medicinal chemist in the areas of oncology, metabolic disorders, urology, and immunology, and discovered 7 clinical candidates. He has been a member of the Microglia Research Unit since its launch and has led several in-house research projects as well as research collaborations. He assumed the present position in August 2022.
Scientific Director
Kengo Saba, Ph.D.
Dr. Saba has been involved in drug discovery research as a pharmacologist in the areas of infectious diseases, inflammatory diseases, rare diseases, and central nervous system diseases. He has more than 20 years of experience in innate immunology research, and discovered 3 clinical candidates.
Patent
WO/2021/193897, PCT/JP2021/012773, (EN) SUBSTITUTED PYRIDAZINE COMPOUND
[Novel NLRP3 inflammasome inhibitors]